Open Access

REVIEW

Microglial TRPV1 in epilepsy: Is it druggable for new antiepileptic treatment?

JIAO HU, JIALU MO, XIANGLIN CHENG^*

The First Affiliated Hospital of Yangtze University, Jingzhou, 434000, China

* Corresponding Author: XIANGLIN CHENG. Email:

(This article belongs to the Special Issue: Neuroimmune Interactions at the Crossroads of Health and Disease)

BIOCELL 2023, 47(8), 1689-1701. https://doi.org/10.32604/biocell.2023.029409

Received 16 February 2023; Accepted 08 May 2023; Issue published 28 August 2023

Abstract

Epilepsy is one of the most common neurological diseases worldwide with a high prevalence and unknown pathogenesis. Further, its control is challenging. It is generally accepted that an imbalance between the excitatory and inhibitory properties of the central nervous system (CNS) leads to a large number of abnormally synchronized neuronal discharges in the brain. Transient receptor potential vanilloid protein type 1 (TRPV1) is a non-selective cation channel that contributes to the regulation of the nervous system and influences the excitability of the nervous system. This includes the release of neurotransmitters, action potential generation due to alterations in ion channels, synaptic transmission, and the changes in glial cells. There is abundant evidence that TRPV1 is widely expressed in the central nervous system (including microglia) and is involved in the development of epilepsy through neuroinflammation. In conclusion, microglial TRPV1 participates in neuroinflammatory reactions and functions as a potential proinflammatory mediator. This presents a novel treatment approach to regulate seizures brought on by neuroinflammation.

---

Keywords

---